The dual ATM and DNA-PK inhibitor XRD-0394 is a novel, potent, and orally active dual inhibitor.733 A phase I clinical trial of XRD-0394 for the treatment of metastatic locally advanced solid tumors and recurrent cancer is recruiting, but no data are yet publicly available (NCT05002140). Here, ATM is linked to cancer.